Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivatives

Mary M Mader; Chuan Shih; Eileen Considine; Alfonso De Dios; Cora Sue Grossman; Philip A Hipskind; Ho-Shen Lin; Karen L Lobb; Beatriz Lopez; José E Lopez; Luisa M Martin Cabrejas; Michael E Richett; Wesley T White; Yiu-Yin Cheung; Zhongping Huang; John E Reilly; Sean R Dinn

doi:10.1016/j.bmcl.2004.11.041

Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivatives

Bioorg Med Chem Lett. 2005 Feb 1;15(3):617-20. doi: 10.1016/j.bmcl.2004.11.041.

Authors

Mary M Mader¹, Chuan Shih, Eileen Considine, Alfonso De Dios, Cora Sue Grossman, Philip A Hipskind, Ho-Shen Lin, Karen L Lobb, Beatriz Lopez, José E Lopez, Luisa M Martin Cabrejas, Michael E Richett, Wesley T White, Yiu-Yin Cheung, Zhongping Huang, John E Reilly, Sean R Dinn

Affiliation

¹ Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. [email protected]

PMID: 15664824
DOI: 10.1016/j.bmcl.2004.11.041

Abstract

The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay.

MeSH terms

Cell Line, Tumor
Cell Proliferation / drug effects*
Cells, Cultured
Heterocyclic Compounds, 2-Ring / chemical synthesis
Heterocyclic Compounds, 2-Ring / pharmacology
Humans
Inhibitory Concentration 50
Structure-Activity Relationship
Sulfonamides / chemical synthesis*
Sulfonamides / pharmacology*
Umbilical Veins / cytology
Vascular Endothelial Growth Factor A

Substances

Heterocyclic Compounds, 2-Ring
Sulfonamides
Vascular Endothelial Growth Factor A